Full Press Release Details
American Society of Hematology (ASH) Annual Meeting 2025 Nosha Farhadfar, Stephen Strickland, Ashish Bajel, Alireza Eghtedar, Brian Garrison, Rochelle Emery, Kanya Rajangam, Gary Schiller, Farhad Ravandi
SNTI Positive Sentiment
Promising results from an ongoing Phase I multicenter study of SENTI-202, a first-in-class, CD33 and/or FLT3 & not endomucin (EMCN), selective off-the-shelf logic gated CAR NK cell therapy in adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Key Takeaway: The ongoing Phase I multicenter study of SENTI-202, a novel CAR NK cell therapy, has shown promising results for adults with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). This therapy selectively targets CD33 and FLT3, representing a significant advancement in treatment options. The findings were presented at the American Society of Hematology (ASH) Annual Meeting 2025.
Price reaction · baseline $2.13 (2025-12-05 close) · hit pre-market · 2 other SNTI headline(s) in the window, move may be shared
day 0 close
+12.2%
day 1
-27.7%
day 3 · peak
-33.6%
Market Sentiment Analysis
POSITIVE FACTORS
- Promising results from the Phase I study.
- First-in-class CAR NK cell therapy.
- Targeting CD33 and FLT3 for R/R AML.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+84%
120-day peak, hindsight
Typical move
76.7%
average across 4 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
SENTI-202
Phase 1 · AML/MDS
Frequently Asked Questions
What is SENTI-202?
SENTI-202 is a first-in-class CAR NK cell therapy targeting CD33 and FLT3.
What type of cancer is being targeted?
The therapy targets Relapsed/Refractory Acute Myeloid Leukemia (R/R AML).
What were the results of the Phase I study?
The Phase I study of SENTI-202 showed promising results for patients.
Where were the findings presented?
The findings were presented at the American Society of Hematology (ASH) Annual Meeting 2025.